FDA Approved Alzheimer's Drug to Reduce Metabolic Syndrome Markers

Alzheimer's medication can reduce inflammation and insulin resistance in patients with metabolic syndrome, according to a clinical trial by scientists at Northwell Health's Feinstein Institute for Medical Research. The findings could be a potential therapeutic intervention for metabolic syndrome, which affects 30 percent of the adults in the United States.
Email bookmark
Font : A-A+

Related Links